Scholarlink

Background <p>Activating somatic <i>KRAS</i> mutations in hotspot loci occur almost universally (&gt; 95%) in pancreatic ductal adenocarcinoma (PDAC). Both the presence of a <i>KRAS</i> mutation and high mRNA expression levels of <i>KRAS</i> in tumor tissue have been associated with worse outcome. Less is known about the expression of KRAS at the protein level and its association with clinical and molecular parameters. In the present study, we investigated the prognostic significance of the KRAS protein level and its relation to <i>KRAS</i> mutation status and the mRNA expression level.</p> Methods <p>A total of 41 PDAC tumors were screened for seven KRAS mutations (p.G12D, p.G12V, p.G12R, p.G12C, p.G12S, p.G13D, p.G12A) by the Wobble-enhanced ARMS method. Whole transcriptome and proteome profiles were obtained using mRNA microarrays (Agilent) and quantitative mass spectrometry-based proteomics (HiRIEF LC–MS/MS), respectively. The clinical outcome was overall survival (OS).</p> Results <p><i>KRAS</i> mutations were identified in 88% of the tumors with p.G12D and p.G12V mutations being the most frequent. Tumors with p.G12V mutation had significantly higher <i>KRAS</i> mRNA expression than tumors with p.G12D, p.G12C, p.G12R or no mutation identified (<i>P</i> &lt; 0.01). KRAS protein levels did not associate significantly to neither <i>KRAS</i> mRNA levels (Spearman’s rho = 0.18, <i>P</i> = 0.28) nor type of <i>KRAS</i> mutation. High KRAS protein level and mutation p.G12V were found to be significantly associated with better (<i>P</i> &lt; 0.01) and worse OS (<i>P</i> &lt; 0.05), respectively.</p> Conclusions <p>The KRAS protein level correlated poorly with <i>KRAS</i> mRNA expression level and was not significantly associated with the type of mutation present. Interestingly, we found that patients with high KRAS protein level in their tumors had a better clinical outcome.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Elevated KRAS protein level is associated with better survival in pancreatic cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • S. M. Stålberg,
  • L. Silwal-Pandit,
  • J. Hamfjord,
  • D. J. H. Nebdal,
  • J. Lehtiö,
  • O. C. Lingjærde,
  • B. S. Skålhegg,
  • E. H. Kure

摘要

Background

Activating somatic KRAS mutations in hotspot loci occur almost universally (> 95%) in pancreatic ductal adenocarcinoma (PDAC). Both the presence of a KRAS mutation and high mRNA expression levels of KRAS in tumor tissue have been associated with worse outcome. Less is known about the expression of KRAS at the protein level and its association with clinical and molecular parameters. In the present study, we investigated the prognostic significance of the KRAS protein level and its relation to KRAS mutation status and the mRNA expression level.

Methods

A total of 41 PDAC tumors were screened for seven KRAS mutations (p.G12D, p.G12V, p.G12R, p.G12C, p.G12S, p.G13D, p.G12A) by the Wobble-enhanced ARMS method. Whole transcriptome and proteome profiles were obtained using mRNA microarrays (Agilent) and quantitative mass spectrometry-based proteomics (HiRIEF LC–MS/MS), respectively. The clinical outcome was overall survival (OS).

Results

KRAS mutations were identified in 88% of the tumors with p.G12D and p.G12V mutations being the most frequent. Tumors with p.G12V mutation had significantly higher KRAS mRNA expression than tumors with p.G12D, p.G12C, p.G12R or no mutation identified (P < 0.01). KRAS protein levels did not associate significantly to neither KRAS mRNA levels (Spearman’s rho = 0.18, P = 0.28) nor type of KRAS mutation. High KRAS protein level and mutation p.G12V were found to be significantly associated with better (P < 0.01) and worse OS (P < 0.05), respectively.

Conclusions

The KRAS protein level correlated poorly with KRAS mRNA expression level and was not significantly associated with the type of mutation present. Interestingly, we found that patients with high KRAS protein level in their tumors had a better clinical outcome.